CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, surgeons, radiation oncologists and scientific and research professionals involved in the basic, translational and clinical research or treatment of gastroesophageal cancers.
  
  LEARNING OBJECTIVES

  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection and sequence of systemic therapy for patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer.
  • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy for the management of gastric/GEJ cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
  • Recall the recent FDA approval of trastuzumab deruxtecan for patients with previously treated HER2-overexpressing gastric/GEJ cancer, and incorporate this treatment strategy into clinical management algorithms.
  • Appreciate the recent FDA approvals of anti-PD-1 antibodies in combination with fluoropyrimidine and platinum-based chemotherapy for previously untreated advanced or metastatic gastric, GEJ and esophageal cancer, and identify patients appropriate for treatment with these strategies.
  • Appraise recently presented clinical trial findings with the use of anti-PD-1 antibodies as adjuvant therapy or as a component of first-line treatment for patients with esophageal cancer, and consider the current and future roles of these strategies.
  • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Presenting Faculty Members
  
  Joseph Chao, MD
  Associate Clinical Professor
  Department of Medical Oncology and Therapeutics Research
  GI Medical Oncology Section
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Advisory Committee: Bristol-Myers Squibb Company, Daiichi Sankyo Inc, MacroGenics Inc, Merck; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Foundation Medicine, Ono Pharmaceutical Co Ltd; Contracted Research: Brooklyn ImmunoTherapeutics, Merck; Data and Safety Monitoring Board/Committee: Yiviva; Speakers Bureau: Merck.
  
  Yelena Y Janjigian, MD
  Associate Attending Physician
  Associate Professor, Weill Cornell Medical College
  Chief, Gastrointestinal Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Imugene, Lilly, Merck, Merck Serono, Pfizer Inc, Rgenix, Zymeworks; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix; Ownership Interest (Stock Options): Rgenix.
  
  Contributing Investigator
  
  Daniel Catenacci, MD
  Associate Professor, Department of Medicine, Section of Hematology and Oncology
  Director, Interdisciplinary Gastrointestinal Oncology Program
  Assistant Director, Translational Research, Comprehensive Cancer Center
  The University of Chicago Medical Center and Biological Sciences
  Chicago, Illinois
  
  Advisory Committee: Astellas, Merck, Seagen Inc, Tempus; Consulting Agreements: Amgen Inc, Archer Pharmaceuticals, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gritstone Oncology, Guardant Health, Lilly, Merck, Natera Inc, Pieris Pharmaceuticals Inc, QED Therapeutics, Seagen Inc, Taiho Oncology Inc, Tempus, Zymeworks; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group; Data and Safety Board: Genentech, a member of the Roche Group, Merck Serono; Speakers Bureau: Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Tempus.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Five Prime Therapeutics Inc.
  
  Release date: May 2021
  Expiration date: May 2022